Entrada Therapeutics, Inc. (TRDA)
6.57
-0.54
(-7.59%)
USD |
NASDAQ |
Sep 10, 13:28
Entrada Therapeutics Total Assets (Quarterly) : 298.88M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 298.88M |
| March 31, 2026 | 335.52M |
| December 31, 2025 | 377.38M |
| September 30, 2025 | 412.90M |
| June 30, 2025 | 448.78M |
| March 31, 2025 | 486.48M |
| December 31, 2024 | 526.32M |
| September 30, 2024 | 554.59M |
| June 30, 2024 | 581.96M |
| March 31, 2024 | 510.84M |
| December 31, 2023 | 469.19M |
| September 30, 2023 | 485.03M |
| Date | Value |
|---|---|
| June 30, 2023 | 493.98M |
| March 31, 2023 | 475.57M |
| December 31, 2022 | 252.06M |
| September 30, 2022 | 274.46M |
| June 30, 2022 | 295.92M |
| March 31, 2022 | 316.70M |
| December 31, 2021 | 305.83M |
| September 30, 2021 | 132.40M |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 43.53M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 15.07M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 65.47M |
| Shareholders Equity (Quarterly) | 233.41M |
| Debt to Equity Ratio | 0.208 |
| Current Ratio | 10.89 |
| Net Debt Paydown Yield | 0.59% |